Present and Future Prospects of Radiation Therapy Using α-Emitting Nuclides
Rattachement africain : jp. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Therapy with α-radiation has issues associated with internal exposure; its clinical use has been avoided. However, phase III clinical tests of the α-emitting nuclide 223 Ra on patients with cancer have been conducted, and results were reported in 2011 to 2012. Since then, research has being carried out on targeted internal therapy by introducing α-emitting nuclides directly into the cancers. For many decades, nontargeted radon therapy has been carried out and is controversial because its mechanism of action is stimulation. The low-level radiation sends powerful signals to upregulate many biological protection systems, which protect against the effects of radiogenic and nonradiogenic toxins. These vital systems prevent, repair, and remove DNA and other biomolecular damage being produced endogenously at a very high rate by the very abundant reactive oxygen species associated with aerobic metabolism. Stimulation of protection systems results in beneficial effects, including a lower risk of cancer. This article reports the results of treatments on 4 patients with cancer and reviews the clinical use of α-radiation from 223 Ra and radon. It discusses the prospect of using the novel 225 Ac-prostate-specific membrane antigen ligand-617 ligand as a therapeutic agent for prostate cancer. It presents a new treatment system that we developed, α-Radiorespir o-Rn, which seems to be extremely effective in treating cancer.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Present and Future Prospects of Radiation Therapy Using α-Emitting Nuclides
- Date Crossref
- 01/01/2018
- Éditeur
- SAGE Publications
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
Tokyo University of Science pays non établi dans la noticeUniversité ou école supérieure
-
Ohu University pays non établi dans la noticeUniversité ou école supérieure
-
Tokyo Ariake University of Medical and Health Sciences pays non établi dans la noticeUniversité ou école supérieure
-
Faculty of Pharmaceutical Sciences Department of Radiation Biosciences pays non établi dans la noticeUniversité ou école supérieure
-
Cuttler and Associates Inc pays non établi dans la noticeEntreprise
-
Lead & Company Co pays non établi dans la noticeEntreprise
Tokyo University of Science, Ohu University et Tokyo Ariake University of Medical and Health Sciences, avec 3 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.